Few moments are more concerning to parents than learning that their infant has a birth defect. Compounding this news is the possibility that the medication used to manage the mother’s mood disorder may have increased the risk for her infant developing a birth defect. As health care professionals, we have an enormous obligation to get the science right. In 2007, an editorial was published in response to 2 large case-control studies, “Teratogenicity of SSRIs: Serious Concern or Much Ado about Little?”1 What have we learned over the ensuing 13 years?
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wisner KL, Oberlander TF, Huybrechts KF. The Association Between Antidepressant Exposure and Birth Defects—Are We There Yet? JAMA Psychiatry. 2020;77(12):1215–1216. doi:10.1001/jamapsychiatry.2020.1512
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: